# UK Rapid Diagnostics Market > UK Rapid Diagnostics Market Research Report: Size, Share, Trend Analysis By Applications (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.96% - **2024:** $ 1,179.11 Million - **2025:** $ 1,284.76 Million - **2035:** $ 3,032 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) **Report ID:** MRFR/MED/43662-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-rapid-diagnostics-market-45342 --- ## Market Summary ## **UK Rapid Diagnostics Market Overview** As per MRFR analysis, the UK Rapid Diagnostics Market Size was estimated at 1.45 (USD Billion) in 2023.The UK Rapid Diagnostics Market Industry is expected to grow from 1.57(USD Billion) in 2024 to 3.15 (USD Billion) by 2035. The UK Rapid Diagnostics Market CAGR (growth rate) is expected to be around 6.535% during the forecast period (2025 - 2035). **Key UK Rapid Diagnostics Market Trends Highlighted** The UK is seeing growth in the rapid diagnostics market caused by the urgent need for fast and accurate testing, especially in the healthcare sector. Advanced technologies like point-of-care testing and home-testing diagnostics have further developed this market. The onset of the COVID 19 pandemic highlighted the need for rapid testing solutions, resulting in increased investment and innovation for the diagnostic solutions industry. Moreover, the rising elderly population and the emergence of chronic diseases further worsen the need for timely diagnostics, making rapid testing an essential aspect in effective patient management. There are opportunities emerging towards the United Kingdom market as there is increased interest from both the private and public sectors to improve the healthcare services. The government’s focus on enhancing the public community health services has resulted in some initiatives aimed at making diagnostic testing readily available. Such emphasis in the decentralization of healthcare services can be favorable for fast diagnostic products in remote and less population dense areas. There is also support from research agencies for the development of diagnostics products which drives the innovation for new tests for various infections and other diseases. There has recently been a change towards digital health which includes funding for telehealth services and other integrated diagnostic service platforms. The use of mobile health applications is increasingly being adopted for remote result delivery from rapid tests and monitoring the patients’ recovery process. The merging of diagnostics into comprehensive health management systems creates an exceptional opportunity to improve patient care in the UK. The focus on preventative healthcare and personalized measures suggests growth prospects in the rapid diagnostics segment, which is beneficial for earlier detection and improved health status outcomes of the British population. **UK Rapid Diagnostics Market Drivers** **Increased Demand for Rapid Testing Solutions Due to Public Health Needs** The COVID-19 pandemic highlighted the critical need for rapid diagnostic testing solutions, resulting in a surge in demand within the UK Rapid Diagnostics Market Industry. This trend is expected to continue as the UK government increases its focus on health security and management of infectious diseases. The UK's response to COVID-19 has led to the establishment of several testing centers and a significant emphasis on rapid testing technologies to enhance response capabilities.Reports indicate that at its height, the UK conducted over 1 million tests per day, reflecting a requirement for rapid diagnostics that can deliver quick results. Organizations like NHS Test and Trace have played a vital role in showcasing the impact of rapid diagnostic solutions on managing public health emergencies. Moving forward, with an estimated annual increase in healthcare spending projected by government investment funding, the UK Rapid Diagnostics Market is positioned for sustainable growth. **Advancements in Technology and Innovation** Technological advancements are transforming the UK Rapid Diagnostics Market Industry by enabling the development of more efficient and accurate diagnostic devices. The growing incorporation of artificial intelligence (AI) and machine learning in diagnostic tests is enhancing the speed of results while ensuring better accuracy. For instance, the UK government has invested in initiatives promoting innovation in healthcare technology, funding numerous projects aimed at developing new diagnostic solutions.This innovative drive is reflected in the increased patent submissions for rapid diagnostic technologies, with a noticeable rise in the last few years, emphasizing the focus on enhancing diagnostic efficiency. Organizations such as UK Research and Innovation are key players in funding and supporting these technological advancements, ensuring the UK remains at the forefront of rapid diagnostics. **Growing Prevalence of Chronic Diseases** The rising prevalence of chronic diseases in the UK is a significant driver for the growth of the UK Rapid Diagnostics Market Industry. Conditions such as diabetes, cardiovascular diseases, and various forms of cancer have been on the rise, increasing the need for early and accurate diagnostic solutions. According to the UK government health statistics, approximately 3.5 million people are diagnosed with diabetes alone, representing a substantial portion of the population requiring regular monitoring and testing.This trend indicates a substantial market potential for rapid diagnostic tests aimed at chronic disease management. Major organizations like Diabetes UK and other health foundations highlight the importance of efficient diagnostic tools in managing these chronic conditions, which is critical for improving patient outcomes. **Supportive Regulatory Environment** The regulatory framework set by the UK government and healthcare organizations is supportive of innovations in the rapid diagnostics sector. With initiatives designed to speed up the approval process for new diagnostic tests, manufacturers are incentivized to innovate and bring products to market quickly. The MHRA (Medicines and Healthcare products Regulatory Agency) has established fast-track pathways for COVID-19 related rapid tests and is now extending these practices to other diagnostic developments.This positive regulatory environment fosters competition and encourages technology adoption, which is essential for growth in the UK Rapid Diagnostics Market Industry. Moreover, the move towards a more streamlined process is expected to boost the overall market significantly, enabling quicker responses to evolving healthcare challenges. **UK Rapid Diagnostics Market Segment Insights** **Rapid Diagnostics Market Application Insights** The UK Rapid Diagnostics Market has seen a considerable shift towards applications that enhance patient outcomes and streamline healthcare services. The diverse applications in this market include Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, and Toxicology Testing, each with its unique importance and significance. Blood Glucose Testing serves as a critical tool for managing diabetes and is widely used in both home settings and clinical environments, showcasing its integral role in disease management.Infectious Disease Testing has gained traction, particularly in the wake of global health crises, as rapid detection can significantly impact treatment timelines and infection control measures.  Additionally, Cardiometabolic Testing captures essential data for evaluating cardiovascular and metabolic health, facilitating early intervention and chronic disease management. Pregnancy Fertility Testing applications empower individuals with timely and reliable results, influencing personal and family health decisions. Fecal Occult Blood Testing remains vital for colorectal cancer screening, enhancing early detection and improving prognosis.Coagulation Testing plays a crucial role in managing bleeding disorders and anticoagulation therapies, while Toxicology Testing has become increasingly significant in both clinical and forensic settings, addressing substance abuse and environmental health concerns.  The ongoing growth in these applications is driven by technological advancements, increasing awareness of preventive healthcare, and a demand for personalized medicine. The dynamic landscape of the UK Rapid Diagnostics Market continues to evolve, presenting opportunities for innovation and improvement in diagnostic accuracy, speed, and accessibility to enhance healthcare delivery across the region. **Rapid Diagnostics Market Product Type Insights** The UK Rapid Diagnostics Market showcases a diverse landscape within its Product Type segment, primarily highlighted by Over the Counter (OTC) Kits and Professional Kits. The demand for OTC Kits has surged, driven by the increasing consumer inclination towards self-testing and the convenience of accessing healthcare solutions at home. This trend reflects a significant shift in healthcare dynamics, as UK citizens seek to take charge of their own health management. Meanwhile, Professional Kits continue to hold a crucial place within clinical settings, offering healthcare professionals reliable, fast results for accurate diagnosis and treatment.The importance of Professional Kits is underscored during public health emergencies, where rapid decision-making is essential. With advances in technology and growing awareness of early disease detection, both OTC and Professional Kits play pivotal roles in enhancing healthcare outcomes. As the UK aims to improve overall health diagnostics, the focus on these product types is expected to expand, highlighting their potential in driving growth within the UK Rapid Diagnostics Market. Furthermore, government initiatives aimed at supporting healthcare innovation will likely bolster the presence of these kits across various healthcare platforms, increasing accessibility and efficiency in diagnostics. **UK Rapid Diagnostics Market Key Players and Competitive Insights** The UK Rapid Diagnostics Market has seen significant growth over the past few years, driven by advancements in technology, increased healthcare needs, and a greater emphasis on rapid test results across various medical fields. The competitive landscape within this market is characterized by a blend of established players and emerging companies, each vying for market share through innovation, strategic partnerships, and robust marketing initiatives. As the demand for point-of-care testing continues to rise, the competition intensifies, with companies focusing on differentiating their product offerings and enhancing customer experience. Factors such as regulatory compliance, product accuracy, and the ability to deliver timely results play pivotal roles in shaping the competitive dynamics in this sector. BioMerieux has solidified its presence in the UK Rapid Diagnostics Market through its commitment to offering high-quality and reliable diagnostic solutions. The company is recognized for its innovative product portfolio, which includes assays for infectious diseases and clinical microbiology, allowing healthcare providers to deliver timely diagnoses and improve patient outcomes. BioMerieux benefits from strong brand recognition and a reputation for excellence in precision diagnostics, which are significant strengths in the competitive landscape. The company's extensive research and development efforts have enabled it to stay ahead of trends and fulfill the evolving needs of the UK healthcare system. Furthermore, BioMerieux's strategic collaborations with healthcare providers and institutions enhance its market reach and facilitate the adoption of its diagnostic solutions across the UK. Abbott Rapid Diagnostics plays a crucial role in the UK Rapid Diagnostics Market, boasting a diverse range of key products that cater to various diagnostic needs, including tests for infectious diseases and chronic conditions. The company is well-known for its innovative testing platforms that emphasize speed and accuracy, ensuring that healthcare professionals receive critical information promptly. Abbott's strengths lie in its ability to leverage advanced technology while maintaining a commitment to quality and regulatory compliance, which is essential in the UK market. The company's ongoing investments in research and development, coupled with strategic mergers and acquisitions, have further broadened its capabilities and product offerings.  Through these strategies, Abbott Rapid Diagnostics continues to strengthen its market presence, providing healthcare providers in the UK with cutting-edge diagnostic tools designed to improve patient care and outcomes. **Key Companies in the UK Rapid Diagnostics Market Include:** - BioMerieux - Abbott Rapid Diagnostics - Sysmex Corporation - Eurofins Scientific - PerkinElmer - Mylab Discovery Solutions - Roche Diagnostics - Quidel Corporation - Hologic - Thermo Fisher Scientific - Danaher Corporation - Siemens Healthineers - Abbott Laboratories - Cepheid - BD **UK Rapid Diagnostics Market Industry Developments** The UK Rapid Diagnostics Market has seen significant developments recently, reflecting the ongoing demand for efficient diagnostic solutions. In September 2023, Abbott Rapid Diagnostics launched a new point-of-care testing platform designed to enhance patient management and streamline workflows in healthcare settings. Major players like Roche Diagnostics and Hologic have also been expanding their product lines, focusing on infectious disease diagnostics to meet rising public health needs.  Additionally, in July 2023, Eurofins Scientific announced the acquisition of a local laboratory to bolster its testing capabilities in the UK, further consolidating its presence in the market. Companies like Thermo Fisher Scientific and Sysmex Corporation are also working on advancing molecular diagnostics, supporting the UK's focus on precision medicine.  The growth in market valuation, particularly post-COVID-19, has reinforced investments in rapid diagnostic technologies, creating a competitive landscape that promotes innovation while responding to emerging healthcare challenges. As of 2022, the UK government reported a surge in the adoption of rapid testing, catalyzing further advancements and collaborations among the key players in the sector. **UK Rapid Diagnostics Market Segmentation Insights** - **Rapid Diagnostics Market Application Outlook** - Blood Glucose Testing - Infectious Disease Testing - Cardiometabolic Testing - Pregnancy Fertility Testing - Fecal Occult Blood Testing - Coagulation Testing - Toxicology Testing - **Rapid Diagnostics Market Product Type Outlook** - Over the Counter (OTC) Kits - Professional Kits ## Market Drivers ### Government Initiatives and Funding Government initiatives and funding are pivotal in supporting the rapid diagnostics market in the UK. The UK government has been actively investing in healthcare infrastructure and research, particularly in the field of diagnostics. This support is aimed at enhancing the capabilities of healthcare systems to respond to emerging health threats. Recent funding allocations have focused on developing rapid testing solutions, which are essential for effective disease management. Such initiatives not only bolster the rapid diagnostics market but also encourage collaboration between public and private sectors, fostering innovation and improving healthcare delivery. ### Growing Focus on Preventive Healthcare The growing focus on preventive healthcare is significantly influencing the rapid diagnostics market. As healthcare systems in the UK shift towards preventive measures, the demand for rapid diagnostic tests is expected to rise. These tests facilitate early detection of diseases, allowing for timely interventions that can prevent complications and reduce healthcare costs. The emphasis on preventive healthcare aligns with national health policies aimed at improving population health outcomes. Consequently, the rapid diagnostics market is likely to benefit from this trend, as more healthcare providers adopt rapid testing solutions to support preventive strategies. ### Increasing Demand for Timely Diagnosis The rapid diagnostics market in the UK is experiencing a surge in demand for timely and accurate diagnostic solutions. This trend is driven by the growing awareness among healthcare providers and patients regarding the importance of early disease detection. The ability to obtain results quickly can significantly influence treatment decisions, thereby improving patient outcomes. According to recent data, the market is projected to grow at a CAGR of approximately 10% over the next five years. This increasing demand is likely to encourage innovation and investment in the rapid diagnostics market, as stakeholders seek to develop more efficient and effective testing methods. ### Rising Prevalence of Infectious Diseases The rapid diagnostics market is significantly impacted by the rising prevalence of infectious diseases in the UK. With the increasing incidence of conditions such as respiratory infections and sexually transmitted diseases, there is a pressing need for rapid testing solutions. The UK government has reported a notable increase in the number of reported cases, which has led to heightened public health initiatives aimed at controlling outbreaks. This situation creates a favorable environment for the rapid diagnostics market, as healthcare providers require efficient tools to diagnose and manage these diseases promptly. The market is expected to expand as a result of this growing need. ### Technological Innovations in Diagnostic Tools Technological innovations are playing a crucial role in shaping the rapid diagnostics market. Advancements in molecular diagnostics, biosensors, and microfluidics are enabling the development of more sophisticated and user-friendly testing devices. These innovations not only enhance the accuracy and speed of diagnostics but also reduce costs, making them more accessible to healthcare facilities across the UK. The integration of artificial intelligence and machine learning into diagnostic processes is also emerging, potentially transforming the landscape of the rapid diagnostics market. As these technologies continue to evolve, they are likely to drive further growth and adoption in the sector. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) is projected to grow at 8.96% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for point-of-care testing, and rising healthcare expenditure. **New opportunities:** - Development of portable diagnostic devices for remote healthcare settings. - Integration of AI-driven analytics in diagnostic platforms. - Expansion of telehealth services incorporating rapid testing solutions. By 2035, the rapid diagnostics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Over-the-Counter (OTC) Kits (Largest) vs. Professional Kits (Fastest-Growing) The market share distribution in the product segment of the UK rapid diagnostics market reveals that Over-the-Counter (OTC) Kits dominate the landscape, holding a significant share of the overall market. This dominance can be attributed to the increasing consumer preference for accessible and easy-to-use diagnostic solutions that do not require a healthcare professional's intervention. In contrast, although Professional Kits hold a smaller market share, they are gaining traction due to their indispensable role in clinical settings where accuracy and reliability are paramount. Growth trends in the product segment are notably influenced by changing consumer behaviors and advancements in technology. The increasing awareness of health issues and the convenience of OTC Kits are propelling their growth. Meanwhile, Professional Kits are positioned for rapid expansion, driven by rising healthcare investments and a growing emphasis on diagnostic accuracy in medical facilities. This dual growth trajectory highlights the evolving landscape of the UK rapid diagnostics market and the need for innovation to meet diverse consumer and healthcare demands. Over-the-Counter (OTC) Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter (OTC) Kits are characterized by their convenience and user-friendliness, catering to individuals seeking immediate results without the need for professional assistance. Their widespread availability in pharmacies and online platforms enhances their appeal, making them the preferred choice for self-diagnosis. On the other hand, Professional Kits, while currently less prevalent in terms of market share, are emerging rapidly due to their critical application in healthcare settings. These kits offer advanced diagnostic capabilities and are essential for accurate testing in various medical environments. The growth of these segments signifies a dynamic shift towards more personalized and accessible diagnostic solutions, where both OTC and Professional Kits complement each other to meet the diverse needs of consumers and healthcare providers. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) In the UK rapid diagnostics market, Blood Glucose Testing holds the largest market share, primarily driven by the increasing prevalence of diabetes and the rising need for continuous glucose monitoring among patients. Other significant segments include Infectious Disease Testing, which, though smaller in share, is rapidly gaining traction due to a heightened focus on health and rapid response needs during health crises. Over the following years, the market is expected to further expand as technological advancements introduce more accurate and accessible testing methods. The growth trends within the UK rapid diagnostics market reveal a strong demand for innovative solutions, particularly in the infectious disease sector, as public health initiatives strive for early detection and management of diseases. Additionally, the rise in home diagnostics is propelling segments like Blood Glucose and Toxicology Testing, catering to consumer preferences for self-management of health. Increased government funding and initiatives aimed at improving healthcare accessibility also play a crucial role in this market's evolution, ensuring a diverse range of applications comes to the forefront. Blood Glucose Testing (Dominant) vs. Infectious Disease Testing (Emerging) Blood Glucose Testing represents a dominant force within the UK rapid diagnostics market, reflecting the urgent need for consistent management among diabetes patients. This category not only emphasizes the convenience of timely results but also underlines the technological innovations propelling portable glucose meters and continuous glucose monitoring systems. Conversely, Infectious Disease Testing is deemed an emerging segment, driven by the demand for rapid identification of pathogens, especially post-pandemic. The focus on this area is critical as public health concerns spur advancements in molecular diagnostics and point-of-care testing technologies, making it an essential growth area for diagnostic firms in the UK. ## Competitive Benchmarking The rapid diagnostics market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for timely and accurate diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which allows for rapid results in various settings. Roche Diagnostics (CH) emphasizes its extensive portfolio and integration of digital health solutions, while Siemens Healthineers (DE) is investing in AI-driven diagnostics to streamline processes and improve accuracy. Collectively, these strategies contribute to a competitive environment that is increasingly reliant on technological innovation and strategic partnerships.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players exerting influence while also facing competition from emerging firms. This fragmentation allows for a diverse range of products and services, catering to various segments of the healthcare market. In October Roche Diagnostics (CH) announced a strategic partnership with a leading telehealth provider to integrate remote diagnostics capabilities into their existing platforms. This move is significant as it positions Roche to capitalize on the growing trend of telemedicine, enabling healthcare providers to offer more comprehensive care through remote monitoring and diagnostics. The partnership is likely to enhance Roche's competitive edge by expanding its service offerings and improving patient access to diagnostic services. In September Siemens Healthineers (DE) launched a new AI-powered diagnostic tool aimed at improving the speed and accuracy of disease detection. This innovation is crucial as it aligns with the increasing demand for rapid diagnostics in clinical settings. By leveraging AI, Siemens Healthineers (DE) not only enhances its product portfolio but also addresses the pressing need for efficiency in healthcare delivery, potentially leading to better patient outcomes and reduced healthcare costs. In August Abbott Laboratories (US) expanded its manufacturing capabilities in the UK, focusing on the production of rapid testing kits. This expansion is indicative of Abbott's commitment to meeting local demand and ensuring supply chain reliability. By increasing its manufacturing footprint, Abbott is likely to enhance its responsiveness to market needs, thereby strengthening its competitive position in the rapid diagnostics sector. As of November current trends in the rapid diagnostics market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage complementary strengths and enhance their service offerings. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can effectively integrate advanced technologies and maintain reliable supply chains are likely to emerge as leaders in this rapidly changing market. ## Recent News & Developments The UK Rapid Diagnostics Market has seen significant developments recently, reflecting the ongoing demand for efficient diagnostic solutions. In September 2023, Abbott Rapid Diagnostics launched a new point-of-care testing platform designed to enhance patient management and streamline workflows in healthcare settings. Major players like Roche Diagnostics and Hologic have also been expanding their product lines, focusing on infectious disease diagnostics to meet rising public health needs.  Additionally, in July 2023, Eurofins Scientific announced the acquisition of a local laboratory to bolster its testing capabilities in the UK, further consolidating its presence in the market. Companies like Thermo Fisher Scientific and Sysmex Corporation are also working on advancing molecular diagnostics, supporting the UK's focus on precision medicine.  The growth in market valuation, particularly post-COVID-19, has reinforced investments in rapid diagnostic technologies, creating a competitive landscape that promotes innovation while responding to emerging healthcare challenges. As of 2022, the UK government reported a surge in the adoption of rapid testing, catalyzing further advancements and collaborations among the key players in the sector. ## Report Scope | MARKET SIZE 2024 | 1179.11(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1284.76(USD Million) | | MARKET SIZE 2035 | 3032.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.96% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Integration of artificial intelligence in rapid diagnostics enhances accuracy and efficiency in disease detection. | | Key Market Dynamics | Technological advancements drive rapid diagnostics market growth, enhancing accuracy and speed of disease detection in the UK. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the overall market valuation of the UK rapid diagnostics market in 2024?** A: The overall market valuation was $1179.11 Million in 2024. **Q: What is the projected market valuation for the UK rapid diagnostics market by 2035?** A: The projected valuation for 2035 is $3032.0 Million. **Q: What is the expected CAGR for the UK rapid diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 8.96%. **Q: Which companies are considered key players in the UK rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What are the two main product segments in the UK rapid diagnostics market?** A: The two main product segments are Over-the-Counter (OTC) Kits and Professional Kits. **Q: What was the market size for Professional Kits in 2024?** A: The market size for Professional Kits was $779.11 Million in 2024. **Q: What is the projected market size for Over-the-Counter (OTC) Kits by 2035?** A: The projected market size for OTC Kits by 2035 is $1000.0 Million. **Q: Which application segment had the highest market size in 2024?** A: In 2024, the Infectious Disease Testing segment had the highest market size at $300.0 Million. **Q: What is the expected market size for Cardiometabolic Testing by 2035?** A: The expected market size for Cardiometabolic Testing by 2035 is $500.0 Million. **Q: How does the market size for Blood Glucose Testing compare between 2024 and 2035?** A: The market size for Blood Glucose Testing increased from $100.0 Million in 2024 to a projected $250.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-rapid-diagnostics-market-45342*